|
|
| (2 intermediate revisions not shown.) |
| Line 1: |
Line 1: |
| | | | |
| | ==Crystal structure of a putative VRC01 germline precursor Fab== | | ==Crystal structure of a putative VRC01 germline precursor Fab== |
| - | <StructureSection load='4jpi' size='340' side='right' caption='[[4jpi]], [[Resolution|resolution]] 2.10Å' scene=''> | + | <StructureSection load='4jpi' size='340' side='right'caption='[[4jpi]], [[Resolution|resolution]] 2.10Å' scene=''> |
| | == Structural highlights == | | == Structural highlights == |
| - | <table><tr><td colspan='2'>[[4jpi]] is a 4 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4JPI OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4JPI FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[4jpi]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4JPI OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4JPI FirstGlance]. <br> |
| - | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene></td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.1Å</td></tr> |
| - | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4jpj|4jpj]], [[4jpk|4jpk]]</td></tr> | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene></td></tr> |
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4jpi FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4jpi OCA], [http://pdbe.org/4jpi PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4jpi RCSB], [http://www.ebi.ac.uk/pdbsum/4jpi PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4jpi ProSAT]</span></td></tr> | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4jpi FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4jpi OCA], [https://pdbe.org/4jpi PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4jpi RCSB], [https://www.ebi.ac.uk/pdbsum/4jpi PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4jpi ProSAT]</span></td></tr> |
| | </table> | | </table> |
| | <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
| Line 21: |
Line 21: |
| | __TOC__ | | __TOC__ |
| | </StructureSection> | | </StructureSection> |
| - | [[Category: Human]] | + | [[Category: Homo sapiens]] |
| - | [[Category: Diwanji, D C]] | + | [[Category: Large Structures]] |
| - | [[Category: Jardine, J]] | + | [[Category: Diwanji DC]] |
| - | [[Category: Julien, J P]] | + | [[Category: Jardine J]] |
| - | [[Category: Schief, W R]] | + | [[Category: Julien J-P]] |
| - | [[Category: Wilson, I A]]
| + | [[Category: Schief WR]] |
| - | [[Category: Anti-hiv-1]]
| + | [[Category: Wilson IA]] |
| - | [[Category: Cd4 binding site-targeting]] | + | |
| - | [[Category: Gp120]] | + | |
| - | [[Category: Immune system]]
| + | |
| - | [[Category: Vrc01 broadly neutralizing antibody]]
| + | |
| Structural highlights
Publication Abstract from PubMed
Vaccine development to induce broadly neutralizing antibodies (bNAbs) against HIV-1 is a global health priority. Potent VRC01-class bNAbs against the CD4 binding site of HIV gp120 have been isolated from HIV-1-infected individuals; however, such bNAbs have not been induced by vaccination. Wild-type gp120 proteins lack detectable affinity for predicted germline precursors of VRC01-class bNAbs, making them poor immunogens to prime a VRC01-class response. We employed computation-guided, in vitro screening to engineer a germline-targeting gp120 outer domain immunogen that binds to multiple VRC01-class bNAbs and germline precursors and elucidated germline-binding crystallographically. When multimerized on nanoparticles, this immunogen (eOD-GT6) activates germline and mature VRC01-class B cells. Thus, eOD-GT6 nanoparticles have promise as a vaccine prime. In principle, germline-targeting strategies could be applied to other epitopes and pathogens.
Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors.,Jardine J, Julien JP, Menis S, Ota T, Kalyuzhniy O, McGuire A, Sok D, Huang PS, Macpherson S, Jones M, Nieusma T, Mathison J, Baker D, Ward AB, Burton DR, Stamatatos L, Nemazee D, Wilson IA, Schief WR Science. 2013 Mar 29. PMID:23539181[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
References
- ↑ Jardine J, Julien JP, Menis S, Ota T, Kalyuzhniy O, McGuire A, Sok D, Huang PS, Macpherson S, Jones M, Nieusma T, Mathison J, Baker D, Ward AB, Burton DR, Stamatatos L, Nemazee D, Wilson IA, Schief WR. Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors. Science. 2013 Mar 29. PMID:23539181 doi:10.1126/science.1234150
|
